Patent intelligence · AR
AR 124425
POLIPÉPTIDOS QUE COMPRENDEN DOMINIOS VARIABLES SIMPLES DE INMUNOGLOBULINA DIRIGIDOS A GLYPICAN-3 Y AL RECEPTOR DE CÉLULAS T
POLIPÉPTIDOS QUE COMPRENDEN DOMINIOS VARIABLES SIMPLES DE INMUNOGLOBULINA DIRIGIDOS A GLYPICAN-3 Y AL RECEPTOR DE CÉLULAS T
Patent details — AR 124425
- Jurisdiction
- AR
- Status
- granted
- Grant date
- Mar 29, 2023
- Expiration
- Mar 24, 2043
- Applicant
- ABLYNX NV [BE]
- CPC classes
- A61P 35/ 00 A I, A61P/3500
Quick answer
AR 124425 (POLIPÉPTIDOS QUE COMPRENDEN DOMINIOS VARIABLES SIMPLES DE INMUNOGLOBULINA DIRIGIDOS A GLYPICAN-3 Y AL RECEPTOR DE CÉLULAS T) is held by ABLYNX NV [BE]. Status: granted. Granted Mar 29, 2023. Expires Mar 24, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABLYNX NV [BE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P 35/ 00 A I, A61P/3500
More from ABLYNX NV [BE]
Related pharmaceutical patents in our USPTO index.
-
WO 2026078159
AGENTS D'ACTIVATION DE CELLULES IMMUNITAIRES ET PROCÉDÉS LES COMPRENANT
granted -
WO 2026030375
NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
granted -
WO 2025262150
MOLÉCULES DE RECRUTEMENT D'ANTICORPS
granted -
AR 133055
DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1
granted -
MX 2025007399
PROTEIN-BASED CONJUGATION CARRIERS
granted -
WO 2025133166
VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE
granted -
WO 2025133252
DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5
granted -
WO 2025133253
EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE
granted
Frequently asked questions
What is US patent 124425?
AR 124425 (POLIPÉPTIDOS QUE COMPRENDEN DOMINIOS VARIABLES SIMPLES DE INMUNOGLOBULINA DIRIGIDOS A GLYPICAN-3 Y AL RECEPTOR DE CÉLULAS T) is held by ABLYNX NV [BE]. Status: granted. Granted Mar 29, 2023. Expires Mar 24, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AR 124425?
ABLYNX NV [BE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AR 124425 expire?
Our index shows an expiration date of Mar 24, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.